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2Abstract
Background and aims: Our objective was to develop an integrated central blood pressure-
aortic stiffness (ICPS) risk score to predict cardiovascular events.
Methods: It was a retrospective cohort study. One hundred chronic kidney disease (CKD)
patients on conservative therapy were included. Pulse wave velocity (PWV), central systolic
blood pressure (cSBP) and central pulse pressure (cPP) were measured. A score was assigned
to tertiles of PWV (0 to 2), cPP (0 to 2) and cSBP (0 to the first and second and 1 to the third
tertile) based on each parameter’s ability to individually predict cardiovascular outcome. The
sum of these scores and three ICPS risk categories as predictors were studied. Finally, we
compared discrimination of the ICPS risk categories with PWV, cSBP and cPP.
Results: Adjusted for age and sex, patients in high and very high ICPS risk categories had
increased cardiovascular risk (HR: 3.52, 95%CI: 1.65-7.49, HR: 7.56, 95%CI: 3.20-17.85,
respectively). High and very high ICPS risk categories remained independent predictors in a
model adjusted for multiple CV risk factors (HR: 4.58, 95%CI: 1.65-7.49, HR: 8.56, 95%CI:
3.09-23.76, respectively). ICPS risk categories (Harrell's C: 0.723, 95%CI: 0.652-0.795)
showed better discrimination than PWV (Harrell's C: 0.659, 95%CI: 0.586-0.732, p=0.028)
and cSBP (Harrell's C: 0.660, 95%CI: 0.584-0.735, p=0.008) and there has been a tendency of
significance in case of cPP (Harrell's C:0.691, 95%CI: 0.621-0.761, p=0,170).
Conclusions: The ICPS score may clinically importantly improve the identification of CKD
patients with elevated cardiovascular risk.
Keywords: chronic renal failure, central blood pressure, central pulse pressure, pulse
wave velocity, survival analysis
3Introduction
Given that cardiovascular (CV) diseases are still the leading causes of mortality worldwide
and that an armamentarium of effective preventive medications is available, it is of utmost
importance to accurately predict CV risk in different populations to increase the health
benefits of CV prevention (5). One group of contenders that may improve CV risk prediction
over and above the classical parameters are measurements that describe arterial stiffness and
central hemodynamic status. These parameters have been extensively investigated in the past
two decades. In all stages of chronic kidney disease (CKD) arterial stiffness is an important
risk factor for cardiovascular events and mortality (13).
The most important marker of arterial stiffness is the carotid-femoral pulse wave velocity
(PWV). It was found to be predictive in different patient populations and is included in the
European hypertension guidelines since 2007. However, the most recent European guideline
on CV risk prevention advised against its use for CV risk assessment in the general population
(12).
Among parameters describing central hemodynamics, central systolic blood pressure (cSBP, a
measure of pressure load) and central pulse pressure (cPP, describing pulsatility) seem to be
the most promising, as they have better predictive values compared to brachial systolic and
pulse pressure in some conditions (1, 7), although no additional advantage was found
compared to brachial pressure in the Framingham Heart Study (8).
Another measure, the augmentation index (Aix) is a wave reflection parameter that also
describes total peripheral resistance. It has also been reported to be an independent predictor
of CV outcomes (6), but results are conflicting (8, 11).
Although most available literature on arterial stiffness investigates the predictive power of
stiffness parameters individually, given that PWV, cSBP, cPP and Aix can be obtained with
most available devices at a single measurement, and that they reflect different aspects of the
vasculature, it seems reasonable to combine their results into a single score to predict vascular
events.
Our aims were to investigate in CKD patients on conservative therapy (1) the predictive
power of PWV, cSBP, cPP and Aix individually for CV events, (2) to translate these
parameters into simple scores based on their tertiles, (3) to establish and test for CV
prediction an integrated parameter as the sum of these scores and based and these scores,
4different risk categories and (4) to test whether the integrated score-based risk category
concept improves CV prediction compared with its components separately.
Methods
It was a retrospective cohort study. Scientific results from this cohort were published
previously (1, 10). Patients were recruited from two tertiary care nephrology outpatient clinics.
Convenience sampling was used with the consecutive inclusion of CKD patients. None of the
patients was hospitalized at the time of baseline investigations. CKD patients in stages 1-5,
not on dialysis therapy, who gave written informed consent for participation, were included.
Patients with atrial fibrillation or with frequent ventricular extrasystoles counteracting with
pulse wave analysis were excluded. After baseline clinical, laboratory, arterial stiffness and
central hemodynamic measurements, patients were followed for a median of 67.6 months
(interquartile range: 38.4-82.6). Follow-up data were collected between April 2007 and July
2014 by yearly telephone interviews either with the patients, their general practitioners or
treating physicians. All endpoint information was verified by original chart review. Follow-up
was censored at the last occurrence of a documented CV event (acute coronary syndrome,
heart failure requiring hospitalization, stroke or transient ischemic attack or peripheral artery
disease with the need for an intervention) or death due to the above CV causes.
The protocol was approved by the local ethical committees of the participating hospitals and
was carried out in accordance with the tenets of the Declaration of Helsinki. All patients gave
written informed consent before participation.
Arterial stiffness, central hemodynamic and blood pressure measurements
All measurements were performed between 10-12 a.m. Patients were allowed to take a non-
standardized light breakfast and took their regular medications at least 3 hours before the
study measurements. Patients were asked to refrain from smoking on the day of the study and
not to consume any caffeine-containing drinks at least 4 hours before the start of the
measurements. Arterial stiffness measurements and blood sampling were done on separate
days within a week.
5Arterial stiffness measurements were carried out in a temperature-controlled room (241C).
Upon arrival after a 5-minute rest, two consecutive brachial blood pressure measurements
were taken one minute apart on each arm in the sitting position with a validated BpTru device
(VSM Medtech, Vancouver, Canada). The mean value was calculated for each arm, and the
higher of these was further taken as brachial systolic and diastolic blood pressure and heart
rate. Subjects were then set in the supine position for a 10-minute acclimatization period.
Arterial stiffness was measured with tonometric method, using the PulsePen device. About
the PWV and cPP measurements we refer our previous publication (1). Aix was measured by
automatic identification of the '1st shoulder' (inflexion point) on the averaged carotid pulse
signal by the PulsePen software. The pressure amplitude following this point divided by the
pulse pressure provided the Aix. CSBP was calculated directly from the carotid pulse
waveform using the calibration considering brachial systolic and diastolic blood pressures.
Epidemiologic and Laboratory data
Baseline data on current smoking, any type of diabetes mellitus, hypertension, coronary artery
disease (previous acute myocardial infarction or coronary intervention), chronic heart failure
(previous diagnosis), peripheral arterial disease (documented by angiography or intervention)
and cerebrovascular disease (previous stroke or transient ischemic attack) were collected by
health record review.
Blood samples for the determination of blood cell count and hemoglobin, serum cholesterol,
triglyceride, and LDL-cholesterol were collected at baseline. Routine blood chemistry
measurements were done directly after blood sampling on a Hitachi auto-analyser. Baseline
eGFR was calculated using the four-variable Chronic Kidney Disease Epidemiology
Collaboration (CKD-EPI) equation.
Statistical analysis
All data analyses were performed using SPSS 23 for Windows or Stata version 13.1.
Continuous data are given as mean and standard deviation, or in case of evidence against a
normal distribution, as a median and interquartile range.
6The primary outcome of the study was the occurrence of the combined endpoint of
cardiovascular events and cardiovascular mortality, as defined above.
To assess the predictive values of the studied parameters for the primary outcome multiple
failure times Cox proportional hazard regression analyses were used with conditional risk set
modeling. This method accommodates for the fact that one patient may have had more than
one event during follow-up.
No a priori power calculations were done for the current analysis, however the sample size for
the original study was based on the observed differences and the distribution of one of the
arterial stiffness measures (cPP) (1). A post hoc power calculation showed power values
ranging from 0.60 to 0.97 for individual arterial stiffness parameters (as continuous variables)
for the prediction of cardiovascular events.
Arterial stiffness and central hemodynamic parameters were analyzed both as continuous and
categorical variables. For the former, these variables were transformed into z-scores to
improve their comparability and thus the associations are given for one SD differences in
PWV, cSBP, cPP and Aix for the CV outcome. Model 1 was adjusted for age and sex, Model
2 was further adjusted for brachial systolic blood pressure, LDL-cholesterol, current smoking,
diabetes, body mass index, known cardiovascular disease and GFR-EPI. As in the cohort all
but one patient had hypertension, we omitted this variable from the adjustment.
Next, patients were divided into tertiles based on their PWV, cSBP, cPP and Aix values,
respectively. Survival was investigated using Kaplan-Meier analysis and Cox-regressions
similar to the ones described above, with arterial stiffness and central hemodynamic
parameters as predictors and CV events or CV mortality as outcome. Polynomial and simple
contrasts were performed to investigate the best scoring for these tertiles. According to these
results, Aix was not related to CV outcome and was excluded from further analysis. There
was a linear association between PWV and cPP and CV outcomes, and accordingly 0, 1 and 2
points were given to the consecutive tertiles. As the risk of CV events or CV mortality only
increased in the third tertile of cSBP, 0 points were given to the first two tertiles and 1 point to
the third.
The integrated central blood pressure- aortic stiffness (ICPS) score was calculated for each
patient by summing the points based on tertiles (range: 0-5 points). Survival was investigated
with Kaplan-Meier and Cox regression analyses (adjusted for age and sex) with ICPS score as
the predictor and CV event or CV mortality as outcome. Given the limited statistical power of
our relatively small sample size, patients were classified into three ICPS risk categories:
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categories were investigated in Kaplan-Meier curves and Cox regressions with adjustment (1)
for age and sex and (2) with further adjustment for brachial systolic blood pressure, LDL-
cholesterol, current smoking, diabetes, body mass index, cardiovascular disease and GFR-EPI.
Finally, the ICPS risk categories and one SD change of each of its components (PWV, cSBP
and cPP) were analyzed in the same Cox-regression model for CV outcomes. To investigate
model discrimination, Harrell's concordance statistics were utilized.
As sensitivity analysis, all of the measurements were performed with Cox regression analyses
considering the occurrence of the first CV event instead of multiple failure time analysis as
well.
Results
Of the 108 patients eligible for inclusion 5 individuals declined participation. Further 3
patients were excluded because of missing baseline or follow-up data, leaving 100 subjects in
the analytical sample.
Table 1 displays baseline characteristics, including concomitant diseases, traditional and
nontraditional CV risk factors, metabolic and vascular parameters.
The causes of kidney disease were heterogeneous (number of cases in parentheses):
glomerulonephritis (n=14), diabetic nephropathy (n=29), hypertensive nephrosclerosis (n=17),
chronic tubulointerstitial nephritis (n=18), vascular cause (n=6), polycystic kidney disease
(n=6), tumor (n=1) and unknown (n=9).
All but one patient received antihypertensive medication (case numbers in parentheses):
angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (n=89), calcium
channel blockers (n=52), diuretics (n=74), β-receptor blockers (n=54), α-receptor blockers 
(n=18), long-acting nitrate (n=15) and centrally acting antihypertensive drugs (n=13), either
alone or in combination. Low dose aspirin was taken by n=36 patients, whereas n=17
individuals took clopidogrel. Sixty-one patients were on statin therapy.
In all, n=37 patients required erythropoietin-stimulating agents, n=35 received calcitriol and
n=9 needed calcium carbonate phosphate binder therapy.
8During follow-up, n=49 cardiovascular events were recorded: n=16 patients died from CV
causes (acute coronary syndrome n=4, stroke n=3, heart failure n=8, peripheral artery disease
n=1) and there were n=33 additional CV events (acute coronary syndrome n=8, stroke n=6,
heart failure n=12 and peripheral artery disease n=7).
Table 2 demonstrates the association of PWV, cSBP, cPP and Aix (per one SD change and
per tertiles) with CV outcomes in models adjusted for age and sex or for traditional CV risk
factors. All the four studied parameters were significantly related to CV outcomes in Model 1.
In the further adjusted Model 2, the association of PWV and cPP was attenuated to non-
significance, while cSBP and Aix showed significant associations. In the analyses of tertiles,
PWV and cPP showed a linear association with the risk of CV outcomes, while for cSBP the
association was non-linear: showing an increase only in the third tertile in Model 1 adjusted
for age and sex. For Aix, no significant association was found, so this parameter was omitted
from the ICPS score calculation. Further adjustment for traditional CV risk factors in Model 2
substantially attenuated the associations and none of them remained significant. Unadjusted
associations are shown as Kaplan-Meyer curves for each tertile of all 4 parameters in Figure
1.
Table 3 demonstrates hazard ratios for CV outcomes by ICPS risk scores and ICPS risk
categories. The risk categories were derived from Cox-models (Table 3) and Kaplan-Meier
(Figure 2A) analyses by collapsing ICPS scores with similar hazard ratios and sufficient
statistical power. Almost half of the patients were classified into the high and very high-risk
categories. Kaplan-Meier survival curves for the three ICPS risk categories are shown in
Figure 2B.
Table 3 shows that the ICPS risk categories are strongly related to the CV outcomes even
after adjustment for traditional CV risk factors. It is also notable, that in Model 2 ICPS risk
categories and diabetes were the only statistically significant predictors, with a higher risk in
the high and very high ICPS risk categories compared to diabetes.
Table 4 demonstrates the results of the comparison of the discriminative ability of the
integrated central pressure-stiffness risk categories with the one standard deviation change of
PWV, cSBP and cPP. All the parameters were adjusted for age and sex. ICPS risk categories
were superior in the discrimination than PWV and cSBP and a tendency was also present in
case of cPP, but the difference was not significant.
When, as sensitivity analysis all the calculations were repeated with the closure of follow-up
at the first event instead of multiple failure time analysis, similar results were found (data are
available from authors for request).
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Our study demonstrated that the concept of an integrated score based on arterial stiffness and
central hemodynamic parameters (ICPS) is strongly related to incident cardiovascular events
in CKD patients. According to our results, people in high and very high ICPS risk categories
are at a remarkably high risk for CV events and have a risk that is stronger than that related to
diabetes, the strongest single predictor among traditional risk factors in our cohort.
Additionally, it is better than PWV and cSBP and tends to be better than cPP which suggests
that it is worth to adding together the predictive power of these parameters.
A recent consensus statement suggests that the combined assessment of more than one
biomarker may improve CV outcome prediction (15). In line with this recommendation, our
study investigated the combined effect of arterial stiffness and central hemodynamic
parameters using a simple score that integrates the predictive information of individual
biomarkers.
Available studies have conflicting results regarding the role of non-invasive markers of
morphological or functional abnormalities of the arterial wall in relation to CV risk. In elderly
patients of the Rotterdam study, the evaluation of carotid intima-media thickness (c-IMT),
peripheral artery disease or PWV marginally improved CV risk stratification over
Framingham risk factors (4, 14). In contrast, in middle-aged subjects from the ARIC study the
detection of increased c-IMT and carotid artery plaques was associated with a significant ~23%
net reclassification index (9).
There are also some data available about the joint evaluation of different non-invasive
hemodynamic biomarkers and their relation to CV outcomes. In the study of Wang et al.,
central systolic blood pressure was superior in CV outcome prediction compared with
brachial systolic blood pressure or brachial or central pulse pressure (16). In the study of
Holewijn et al., using net reclassification improvement analysis, CV risk stratification
improved by adding non-invasive vascular risk markers, like PWV, Aix or cSBP to traditional
risk factors in women, however the association was weaker in men and was limited to men at
intermediate risk (3). These results suggest that the joint evaluation of different vascular
biomarkers may have perspectives, but age and sex could influence the results. Throughout
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our study, we adjusted for age and sex and however ICPS risk categories still remained robust
predictors of CV events.
There are multiple potential advantages of the ICPS score concept. First, PWV, cSBP and cPP
can easily be estimated with most of the available devices (e.g. tonometric,
mechanotransducer-based or oscillometric) that measure arterial stiffness and use pulse wave
analysis. The ICPS score is determined in a non-invasive manner without blood sampling,
which is required for traditional risk scores. Furthermore, it could help to bridge the huge
problem of diverging methodologies. Thanks to creative engineers newer and newer devices
are marketed that estimate these parameters in simpler ways, but the actual results of these
devices are not interchangeable. Our ICPS score based on tertiles in a given population could
be a universal parameter. Of course, the tertiles of each parameter should be defined for each
device, but probably no equations are required to translate results between devices. Although
our studied three parameters correlate with each other, but our results demonstrate, that it is
worth to integrate them into one score as it can produce a very strong predictor parameter.
As the ICPS score is based on a limited sample of CKD patients, we do not recommend its
calculation using the cutoff values from our sample, not even on CKD patients on
conservative therapy. A valid risk score should be based on large databases with a much
higher number of events that enables the investigation of each parameter involved in the score
(2). However, as our ICPS risk categories in the present rudimentary form are much stronger
predictors than diabetes in our cohort, we think that the publication of our results in this form
can generate important discussion and further studies. A great scientific potential of this
concept is related to the fact that there are other cohorts in divergent races with available
PWV, cSBP and cPP measurements, so our finding on ICPS risk categories could easily be
broaden for different patient populations. Such cohorts are for example the Framingham Heart
Study cohort (8) or the Nijmegen Biomedical Study (3).
There are some limitations of our study that has to be acknowledged. During tonometric
arterial stiffness measurements patients with atrial fibrillation are excluded because of
methodological considerations, so a proportion of patients cannot be involved into our new
risk stratification method. Due to the low number of participants and outcome events, our
study is underpowered and thus the exact thresholds for scoring or the relative contribution of
individual parameters could not have been exactly defined. So, the aim of the present study is
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not to define the final score but to report the possible advantages of this new concept of a
combined risk score based on arterial stiffness and central hemodynamic parameters.
In conclusions, our integrated score and the constructed ICPS risk categories provided strong
and robust association with CV outcomes in chronic kidney disease patients on conservative
therapy, which highlights the possible advantages of the combined measure of arterial
stiffness and central hemodynamic parameters for CV risk prediction.
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Figure legends
Figure 1.
Kaplan-Meier survival curves for each parameter studied with cardiovascular events (CV
mortality plus CV events) as outcome. Panel A: pulse wave velocity; Panel B: central systolic
blood pressure; Panel C: central pulse pressure; Panel D: augmentation index.
Figure 2.
Kaplan-Meier survival curves for the integrated central pressure-stiffness (ICPS) risk scores
and ICPS risk categories for cardiovascular events (CV mortality plus CV events, adjusted for
age and sex) as outcomes. Panel A: ICPS risk score groups; Panel B: ICPS risk categories.
Table 1. Baseline demographic, clinical and laboratory characteristics (n=100).
Male n 48
Age (years) 66.00 (58.25-75.00)
BMI (kg/m2) 27.63 (25.24-30.49)
Current smoker 12
Diabetes mellitus 44
Baseline cardiovascular disease 64
Coronary artery disease 13
Chronic heart failure 19
Cerebrovascular disease 24
Peripheral artery disease 53
Framingham CVD score (point) 22.89 (13.09)
eGFR (ml/ min per 1.73m2), 35.74 (23.15-49.43)
Hgb (g/l) 126.89 (14.32)
Chol (mmol/l) 4.81 (4.28-5.33)
Tg (mmol/l) 1.80 (1.15-2.60)
LDL (mmol/l) 2.57 (0.84)
SBP (mm Hg) 135.50 (120.31-145.44)
DBP (mm Hg) 73.12 (9.70)
HR (1/ min) 62.25 (57.50-72.63)
PP (mm Hg) 60.38 (50.56-70.38)
PWV (m/s) 11.26 (8.90-14.90)
Aix (%) 21.53 (15.35-26.83)
cSBP (mm Hg) 124.33 (14.50)
cPP (mm Hg) 48.58 (42.75-60.38)
Categorical parameters are presented as n, numbers can be also considered as percentage.
Continuous data are presented as mean (SD) or median (interquartile range).
Aix: augmentation index; BMI: body mass index; Chol: cholesterol; cPP: central pulse
pressure; cSBP: central systolic blood pressure; DBP: brachial diastolic blood pressure;
eGFR: estimated glomerular filtration rate; Framingham CVD: Framingham 10 Year Risk of
General Cardiovascular Disease Score; Hgb: hemoglobin; HR: heart rate; LDL: low-density
lipoprotein; n: case number; PP: brachial pulse pressure; PWV: carotid-femoral pulse wave
velocity; SBP: brachial systolic blood pressure; Tg: triglyceride.
Table 2. Cox models with cardiovascular morbidity and mortality as outcome and individual
arterial stiffness and central hemodynamic parameters as predictors.
Model 1 Model 2
Variable Hazardratio 95% CI P-value
Hazard
ratio 95% CI P-value
PWV (per 1SD)
1.467 1.182 1.821 <0.001 1.227 0.865 1.740 0.253
cSBP (per 1SD)
1.452 1.054 2.001 0.023 2.935 1.342 6.418 0.007
cPP (per 1SD)
1.636 1.183 2.262 0.003 1.539 0.980 2.416 0.061
Aix (per 1SD)
1.381 1.067 1.788 0.014 1.399 1.041 1.879 0.026
Model 1 Model 2
Variable Tertile N Range Hazardratio 95% CI P-value
Hazard
ratio 95% CI P-value
PWV
1st 33 6.5-9.8 m/s 1 (ref.) 1 (ref.)
2nd 34 9.9-13.0 m/s 1.867 0.636 5.480 0.256 0.777 0.231 2.618 0.684
3rd 33 13.2-27.2 m/s 4.072 1.400 11.841 0.010 1.284 0.386 4.273 0.684
cSBP
1st 33 81.5-117.0 mmHg 1 (ref.) 1 (ref.)
2nd 33 119.0-129.8 mmHg 0.827 0.325 2.106 0.691 1.052 0.331 3.338 0.932
3rd 34 130.0-167.8 mmHg 2.308 1.051 5.071 0.037 2.675 0.560 12.772 0.217
cPP
1st 34 23.3-45.0 mmHg 1 (ref.) 1 (ref.)
2nd 33 45.3-56.3 mmHg 1.608 0.605 4.270 0.341 1.482 0.492 4.469 0.484
3rd 33 56.5-92.3 mmHg 3.712 1.492 9.235 0.005 3.697 0.988 13.830 0.052
Aix
1st 33 7.0-17.8% 1 (ref.) 1 (ref.)
2nd 34 18.0-24.8% 1.897 0.853 4.219 0.117 1.758 0.701 4.406 0.229
3rd 33 25.7-54.5% 1.658 0.665 4.132 0.278 2.049 0.708 5.928 0.186
Model 1 is adjusted for age and sex.
Model 2 is adjusted for age, sex, brachial systolic blood pressure, LDL-cholesterol, current
smoking, diabetes mellitus, body mass index, cardiovascular disease, hypertension, GFR-EPI.
Aix: augmentation index; CI: confidence intervals; cPP: central pulse pressure; cSBP: central
systolic blood pressure; PWV: carotid-femoral pulse wave velocity. Bold values demonstrate
significance when p<0.05.
Table 3. The relation of integrated central blood pressure- aortic stiffness (ICPS) risk score
and ICPS risk categories with cardiovascular morbidity and mortality based on Cox
proportional hazard regression models.
N
Hazard
ratio 95% CI P-value
ICPS risk score
Model 1
0 18 1 (ref.)
1 17
1.831 0.339 9.876 0.482
2 16
1.528 0.233 10.018 0.659
3 24
5.719 1.298 25.208 0.021
4 13
4.236 0.849 21.131 0.078
5 12
11.105 2.366 52.120 0.002
ICPS risk categories
Model 1
Average 51 1 (ref.)
High 37
3.517 1.650 7.494 0.001
Very high 12
7.559 3.201 17.850 <0.001
Model 2
Average 51 1 (ref.)
High 37
4.583 1.867 11.253 0.001
Very high 12
8.563 3.086 23.758 <0.001
Diabetes 44
3.073 1.680 5.621 <0.001
Model 1 is adjusted for age and sex.
Model 2 is adjusted for age, sex, brachial systolic blood pressure, LDL-cholesterol, current
smoking, diabetes mellitus, body mass index, cardiovascular disease and GFR-EPI.
ICPS: integrated central blood pressure- aortic stiffness. Bold values demonstrate significance
when p<0.05.
1Table 4. Comparison of the discriminative ability of the integrated central blood pressure-
aortic stiffness risk categories with the one standard deviation change of pulse wave velocity,
central systolic blood pressure and central pulse pressure (Harell’s C-statistics).
Variable Coefficient Standard error 95% CI P-value
ICPS risk categories 0.723 0.036 0.652 0.795 <0.001
PWV 0.659 0.037 0.586 0.732 <0.001
cSBP 0.660 0.038 0.584 0.735 <0.001
cPP 0.691 0.035 0.621 0.761 <0.001
ICPS risk categories vs PWV 0.065 0.029 0.007 0.122 0.028
ICPS risk categories vs cSBP 0.064 0.024 0.017 0.110 0.008
ICPS risk categories vs cPP 0.032 0.023 -0.014 0.079 0.170
CI: confidence intervals; ICPS risk categories: integrated central blood pressure- aortic
stiffness risk categories; PWV: carotid-femoral pulse wave velocity; cSBP: central systolic
blood pressure; cPP: central pulse pressure. Bold values demonstrate significance when
p<0.05.
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